The results shed light on the long-term effects of Wegovy, and could boost Novo Nordisk's case to insurers and governments to ...
One study found that about 67% of patients taking Structure Therapeutics’s pill lost over 6% of their weight and about 33% ...
Investors interested in the pharmaceutical industry are currently excited about the anti-obesity market. Weight-loss ...
Amid the growing popularity of drugs used for weight loss like Ozempic, Wegovy, Mounjaro and Zepbound, one question has ...
Eli Lilly and Novo Nordisk are, so far, the kings of the weight-loss gold rush. Thanks to their medicines, Zepbound and ...
Some people with obesity have a genetic profile that contributes to what is called a “hungry gut” — that is, they feel full ...
In a letter to Bernie Sanders, Novo Nordisk said it only retains 60% of the list price of either Ozempic or Wegovy ...
After investors frowned on Structure Therapeutics’ oral GLP-1 data in December 2023, the biotech is back with a new cut ...
Structure’s once-daily oral drug, GSBR-1290, belongs to the same class of treatments as Novo Nordisk’s blockbuster weight-loss drug Wegovy and Eli Lilly’s Zepbound ... better than our expectations,” ...
Structure Therapeutics’ American depositary receipts gained more than 6% premarket on Monday after the company said its ...
Many companies hope to compete with Novo Nordisk’s and Eli Lilly’s fast-selling GLP-1 drugs for diabetes and weight loss. Structure is among them ... rather than injected like Novo’s Wegovy or Lilly’s ...
The campaign comes following an update to the FDA-approved label for Wegovy ®, including the removal of body mass index descriptors from the weight-management indication and the addition of a new ...